What are the recommended diagnostic workup and treatment options for an infant with suspected severe combined immunodeficiency (SCID)?

Severe Combined Immunodeficiency (SCID)

Immediate Recognition and Diagnostic Workup

SCID is a pediatric emergency requiring immediate recognition and urgent intervention—survival depends critically on diagnosis and treatment before 3.5 months of age, with transplantation in the neonatal period (first 28 days) yielding the best outcomes (95% vs 76% survival). 1

Clinical Presentation

Suspect SCID in any infant presenting with:

• Recurrent, persistent, or severe infections (bacterial, viral, fungal, or opportunistic organisms like Pneumocystis jirovecii)
• Chronic diarrhea and failure to thrive
• Persistent thrush or skin rashes
• Infections that disseminate rather than remain localized
• Family history of early infant death or known immunodeficiency 1

Diagnostic Algorithm

Step 1: Initial Laboratory Screening

• Complete blood count with differential: Look for lymphopenia (absolute lymphocyte count typically <2,500-3,000/mm³ in infants)
• Quantitative immunoglobulins: Expect low/absent IgA and IgM; IgG may be normal initially due to maternal transfer
• Chest imaging: Absent thymic shadow is highly suggestive (though present in some forms like CD3δ or coronin 1A deficiency) 1

Step 2: Confirmatory Testing

• Flow cytometry for lymphocyte subsets:
  • T-cell count <1,500/mm³ is concerning
  • Assess CD3+, CD4+, CD8+, CD19+, CD16/56+ populations
  • Evaluate naive T cells (CD45RA+): <50% naive cells warrants further workup
• T-cell proliferation assays: Mitogen stimulation (PHA) will show profoundly reduced or absent response
• TREC (T-cell receptor excision circle) assay: Very low or absent in SCID (now part of newborn screening in many regions) 2, 1

Step 3: Determine T-cell Origin (if T cells present)

• Maternal engraftment testing: If T cells are present, determine if they are maternal origin (indicates SCID with maternal T-cell engraftment) or autologous (suggests leaky SCID or alternative combined immunodeficiency)
• Use flow cytometry for HLA typing or chimerism studies 1

Step 4: Genetic Testing

• Pursue molecular diagnosis to identify specific gene defect (>20 possible genes including IL2RG, JAK3, ADA, RAG1/2, DCLRE1C, others)
• This guides prognosis, genetic counseling, and may influence treatment approach (especially for ADA deficiency) 3, 4

Immediate Management Protocol

Infection Prevention (Initiate Immediately Upon Suspicion)

1. Isolation and Prophylaxis

• Strict protective isolation: Avoid contact with crowds, sick individuals, and daycare settings
• Hospital isolation: Private room with infection control precautions
• PCP prophylaxis: Trimethoprim-sulfamethoxazole 5 mg/kg/day (trimethoprim component) orally 3 times weekly. Alternatives: pentamidine 5 mg/kg IV every 4 weeks, dapsone 1 mg/kg/day, or atovaquone 30 mg/kg/day 1
• Consider palivizumab during RSV season (though IVIG provides RSV antibodies) 1

2. Blood Product Precautions

• Only irradiated, CMV-negative, leukocyte-depleted blood products to prevent transfusion-associated GVHD and CMV transmission 1

3. Vaccine Restrictions

• Absolutely no live vaccines: No rotavirus, BCG, oral polio, MMR, varicella, yellow fever, or oral typhoid
• Inactivated vaccines may be given but will likely be ineffective 1

4. Immunoglobulin Replacement

• Initiate IVIG immediately: 400-600 mg/kg every 3-4 weeks (or subcutaneous equivalent)
• Provides passive immunity while awaiting definitive therapy 1

5. Aggressive Infection Management

• Low threshold for empiric broad-spectrum antimicrobials at first sign of infection
• Prolonged treatment courses (clearance is delayed compared to immunocompetent hosts)
• Early investigation of any fever or clinical deterioration 1

Definitive Treatment

Hematopoietic stem cell transplantation (HSCT) is the definitive curative treatment and should be pursued emergently—outcomes are dramatically better when performed before 3.5 months of age and before onset of infections. 1

Treatment Hierarchy

First-line: HLA-matched sibling or matched family donor HSCT

• No conditioning required for matched sibling donors
• Best outcomes with minimal toxicity 4, 5

Second-line (if matched donor unavailable):

For ADA deficiency specifically:

• Autologous gene therapy (if available): Recent studies show 100% overall survival and 90-95% engraftment with nonmyeloablative conditioning
• PEG-ADA enzyme replacement therapy: 30 U/kg IM twice weekly as bridge or if HSCT/gene therapy unavailable (though expensive and provides incomplete immune reconstitution) 1, 4

For other SCID types:

• Gene therapy for IL2RG-deficient SCID (if available and appropriate)
• HLA-mismatched family donor or matched unrelated donor HSCT with reduced-intensity conditioning (improved outcomes in recent years make this preferable to prolonged supportive care) 4, 5

Critical Timing Considerations

The evidence is unequivocal: transplantation before 3.5 months of age yields 95% survival versus 76% when performed later, and neonatal transplantation (first 28 days) shows significantly improved T-cell development. Definitive therapy before infectious complications provides the best outcomes. 1

Common Pitfalls to Avoid

1. Delaying workup in infants with "just" recurrent infections—SCID is rapidly fatal without treatment
2. Administering live vaccines before ruling out SCID (rotavirus vaccine has caused severe disease in undiagnosed SCID infants) 1
3. Using non-irradiated blood products (can cause fatal GVHD) 1
4. Missing maternal T-cell engraftment (T cells present doesn't rule out SCID—must determine origin) 1
5. Waiting for genetic confirmation before initiating protective measures (begin prophylaxis and isolation immediately upon clinical suspicion)
6. Underestimating infection severity (standard antimicrobial courses are inadequate; use prolonged therapy) 1

Consultation and Follow-up

Immediate consultation with a clinical immunologist experienced in SCID management is mandatory. Referral to a tertiary center with HSCT capability should occur urgently. 1 Newborn screening programs using TREC assays have dramatically improved early identification, enabling pre-symptomatic treatment with superior outcomes. 2, 1, 3